PD-L1

Assets acting on this target.

Class
anti-PD-L1 monoclonal antibody
Pathway
PD-1/PD-L1 immune checkpoint blockade

PD-L1 (programmed death-ligand 1) is a cell-surface protein expressed on tumor cells and on various normal and immune cells. It binds the receptor PD-1 on activated T lymphocytes, delivering an inhibitory signal that dampens T-cell activity. This interaction is part of a normal feedback system that limits immune responses and protects healthy tissue from collateral damage during inflammation. Many tumors exploit this pathway by upregulating PD-L1, effectively disguising themselves from immune attack by engaging PD-1 on tumor-infiltrating T cells. Agents that block PD-L1 (or its partner PD-1) interrupt this inhibitory signal, releasing a brake on T-cell function and allowing the immune system to recognize and attack cancer cells more effectively. This general strategy, known as immune checkpoint blockade, has broad relevance across many solid tumor types where immune evasion via this axis contributes to disease progression. Because the pathway is a normal regulator of immune tolerance, blocking it can also unleash immune activity against healthy tissue, producing inflammatory side effects. PD-L1-directed antibodies are one of two principal ways to interrupt this axis, the other being direct blockade of the PD-1 receptor itself, and various modalities including antibody-drug conjugates have been explored to combine checkpoint blockade with direct tumor cell targeting.

By indication

PD-L1 drugs compared

13 drugs, stage by indication
13 drugs acting on PD-L1: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AtezolizumabChugai Pharma, Rochemonoclonal antibodyApprovedApproved in Bladder Cancer; Approved in Colorectal Cancer; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Non-Small Cell Lung Cancer; Approved in Small Cell Lung Cancer
AvelumabMerck KGaAmonoclonal antibodyApprovedApproved in Merkel Cell Carcinoma; Approved in Renal Cell Carcinoma; Approved in Urothelial Carcinoma
DurvalumabAstraZenecamonoclonal antibodyApprovedApproved in Biliary Tract Cancer; Approved in Bladder Cancer; Approved in Endometrial Cancer; Approved in Hepatocellular Carcinoma; Approved in Non-Muscle Invasive Bladder Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Small Cell Lung Cancer; Phase 3 in Ovarian Cancer; Phase 3 in Renal Cell Carcinoma; Phase 3 in Urothelial Carcinoma
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)Rochemonoclonal antibodyApprovedApproved in Bladder Cancer; Approved in Hepatocellular Carcinoma; Approved in Melanoma; Approved in Non-Small Cell Lung Cancer; Approved in Small Cell Lung Cancer
AdebrelimabJiangsu Hengrui Pharmaceuticalsmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Small Cell Lung Cancer
Envafolimab3D Medicines Inc., Ascletis Pharma, Glenmark Pharmaceuticals Ltd., Simcere Pharmaceutical, Suzhou Alphamabmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 2 in Chronic Hepatitis B; Phase 2 in Endometrial Cancer; Phase 2 in HIV
Fetrastobart vedotinPfizer, Seagenantibody-drug conjugatePhase 3Phase 3 in Non-Small Cell Lung Cancer
SugemalimabCejemlyCStone Pharmaceuticals, Ewopharma, Istituto Gentili S.R.L., Laboratorios Stein S.A., Pfizermonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
TagitanlimabSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.monoclonal antibodyPhase 3Phase 3 in Nasopharyngeal Carcinoma; Phase 2 in HR+/HER2- Metastatic Breast Cancer; Phase 2 in Non-Small Cell Lung Cancer
HLX43Shanghai Henlius Biotechantibody-drug conjugatePhase 2/3Phase 2/3 in Non-Small Cell Lung Cancer; Phase 2 in HR+/HER2- Metastatic Breast Cancer
177Lu-RAD204Radiopharm Theranostics, LtdradiopharmaceuticalPhase 1Phase 1 in Non-Small Cell Lung Cancer
BPI-371153Betta Pharmaceuticals Co.small moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer
IBC-Ab002Immunobrain Checkpointmonoclonal antibodyPhase 1Phase 1 in Alzheimer's Disease

← all mechanisms